↓ Skip to Main Content
Thasso
Thasso the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs

search: thasso

Log in

Main Navigation

  • english
    • english
    • français
    • deutsch
    • italiano
    • español
    • português
  • thasso
  • thasso post
  • thasso toolbox
    • theragenomics: useful links
    • theragenomics: biomarkers
    • theragenomics: companion tests
    • theragenomics: drug labels with annotated information
    • theragenomics: drugs and genes
    • theragenomics: the world of alleles
    • theragenomics: allele-related guideline information
    • drug interactions
    • drug information
    • drug adverse reactions
    • drugs: risk evaluation and mitigation strategies (REMS)
    • theragenomics: videos
  • thasso academy
    • health authorities
    • patient & consumer health
    • public domain
      • Swiss Academy of Medical Sciences
      • EUPATI The European Patients’ Academy on Therapeutic Innovation
    • companies
    • products
    • about
  • thasso community
    • thasso: simple chat
    • thasso: video chat
    • theragenomics: survey at thasso
      • survey participants
    • forum
      • patient groups / subgroups
      • group
      • lounge
      • events
      • gallery
  • thasso: about
    • vision
    • background
    • the apomediary patient
    • contact
    • disclaimers
    • policies
  • donations
    • thasso – thank you
    • Donation Confirmation

Tag: Codeine-containing Cough-and-Cold Medicines

Codeine cough-and-cold medicines in children: A never ending story – FDA evaluating potential risk of serious side effects

By Joseph Gut - thasso Posted on July 7, 2015 Posted in Genetic Susceptibility, New Safety Information, Thasso Post, Theragenomic Medicine Tagged with American Food & Drug Administration (FDA), Codeine, Codeine-containing Cough-and-Cold Medicines, CYP2D6, CYP2D6 Extensive Metabolizer Patient Subgroup, CYP2D6 Poor Metabolizer Patient Subgroup, CYP2D6 Ultrarapid Metabolizer Patient Subgroup, European Medicines Agency (EMA), Morphine, Obstructive Sleep Apnea Syndrome
Codeine cough-and-cold medicines in children: A never ending story – FDA evaluating potential risk of serious side effects

July 6. 2015 – The American Food and Drug Administration (FDA) is once more investigating the safety of using codeine-containing medicines to treat coughs and colds in children under 18 years because of the potential for serious side effects, including …

Codeine cough-and-cold medicines in children: A never ending story – FDA evaluating potential risk of serious side effects Read more »

Footer Menu

  • english
  • thasso
  • thasso post
  • thasso toolbox
  • thasso academy
  • thasso community
  • thasso: about
  • donations
Copyright © 2025 Thasso | Powered by Responsive Theme